Trial of Primary Prophylaxis With rhTPO Administered to Patients With High Risk Sarcoma Receiving Intensive Chemotherapy

Completed · Phase 3

Conditions studied: Sarcoma

In brief

Intensive chemotherapy is often associated with low platelet counts often requiring platelet transfusions to maintain platelet counts. In previous clinical studies administration of rhTPO has been demonstrated to increase platelet counts.

Key facts

Study ID
NCT00283582
Run by
M.D. Anderson Cancer Center
People needed
50
Starts
2001-06-01
Expected to finish
2004-11-01
Last updated by the study team
2018-10-30

Who can join

Age: 13 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.